PRME (Prime Medicine) LT-Debt-to-Total-Asset: 0.36 (As of Mar. 2026)


PRME Prime Medicine Inc PRME
25 GF Score
Price $3.22
! 4 Warning Signs
View Full Analysis

What is Prime Medicine LT-Debt-to-Total-Asset?

Prime Medicine PRME +1.26% 25 LT-Debt-to-Total-Asset is 0.36 as of Mar. 2026. GuruFocus rates PRME with a GF Score™ of 25/100. The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Prime Medicine's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.36.

Prime Medicine's long-term debt to total assets ratio increased from Mar. 2025 (0.35) to Mar. 2026 (0.36). It may suggest that Prime Medicine is progressively becoming more dependent on debt to grow their business.

Prime Medicine  (NAS:PRME) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Prime Medicine LT-Debt-to-Total-Asset Related Terms

Prime Medicine LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Prime Medicine's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prime Medicine LT-Debt-to-Total-Asset Chart

Prime Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.01 0.05 0.02 0.13 0.32

Prime Medicine Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.40 0.29 0.32 0.36
PRME
25GF Score
Prime Medicine Inc PRME
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prime Medicine LT-Debt-to-Total-Asset Calculation

Prime Medicine's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=108.29/342.733
=0.32

Prime Medicine's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=105.966/294.73
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.36 mean?
Prime Medicine (PRME) has a LT-Debt-to-Total-Asset of 0.36 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Prime Medicine and its competitors.
Is Prime Medicine's LT-Debt-to-Total-Asset too high?
Prime Medicine's current LT-Debt-to-Total-Asset is 0.36. Overall, Prime Medicine has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's LT-Debt-to-Total-Asset compare to IMMX and SGP?
Prime Medicine's LT-Debt-to-Total-Asset of 0.36 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Prime Medicine and its competitors. Prime Medicine's current LT-Debt-to-Total-Asset is 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current LT-Debt-to-Total-Asset of 0.36. The current LT-Debt-to-Total-Asset is 0.36. Prime Medicine's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Prime Medicine (PRME), the current LT-Debt-to-Total-Asset is 0.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prime Medicine Business Description

Address 60 First Street, Cambridge, MA, USA, 02141
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
25GF Score

Get the complete analysis for PRME

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.22
Price